| Literature DB >> 30599464 |
Saw Thu Wah1,2, Hathairad Hananantachai3, Jintana Patarapotikul3, Jun Ohashi4, Izumi Naka4, Pornlada Nuchnoi1,5.
Abstract
BACKGROUND: During Plasmodium falciparum infection, microRNA expression alters in brain tissue of mice with cerebral malaria compared to noninfected controls. MicroRNA regulates gene expression post-transcriptionally to influence biological processes. Cerebral malaria pathology caused mainly by the immunological disorder. We hypothesize that single-nucleotide polymorphism in a microRNA influences microRNA biogenesis or target gene recognition and altering susceptibility to cerebral malaria.Entities:
Keywords: Thai; cerebral malaria; microRNA SNP; rs2910164; rs57095329; rs895819
Mesh:
Substances:
Year: 2019 PMID: 30599464 PMCID: PMC6393659 DOI: 10.1002/mgg3.529
Source DB: PubMed Journal: Mol Genet Genomic Med ISSN: 2324-9269 Impact factor: 2.183
Figure 1Workflow for selection of candidate microRNA SNPs
Figure 2microRNAs associated with cytoadhesion, immunological response, inflammatory response, and neuronal apoptosis. The microRNA SNPs data that related to at least two of the four mechanisms are listed in the Supporting Information Table S1
Figure 3Chromosomal locations of microRNA‐27a SNP, rs895819 (a), and microRNA‐146a SNPs, rs2910164 and rs57095329 (b). Bioinformatics target gene prediction with or without experimental validation for microRNA‐27a (c) and microRNA‐146a (d). ABCA1: ATP‐binding cassette subfamily A member 1; APAF 1: apoptotic peptidase activating factor 1; ATP10B: ATPase phospholipid transporting 10B; ICAM: intercellular adhesion molecule 1; IL‐10: interleukin‐10; IRAK1: IL‐1 receptor‐associated kinase 1; NFE2L2: nuclear factor erythroid 2 like 2; PTGS2: prostaglandin‐endoperoxide synthase 2 /cyclooxygenase 2; PTTG1: pituitary tumor‐transforming 1; TRAF6: TNF receptor‐associated factor 6; UTR: untranslated region; VCAM1: vascular cell adhesion molecule 1; ZSWIM 4: zinc finger SWIM‐type containing 4
Hardy–Weinberg Equilibrium (HWE) and inbreeding coefficient [F(is)] of miRSNPs
| miRSNPs | Observed genotype | Expected genotype | HWE |
| ||||
|---|---|---|---|---|---|---|---|---|
| rs895819 | TT | TC | CC | TT | TC | CC | ||
| CM | 47 | 51 | 12 | 48 | 49 | 13 | 0.74 | −0.033 |
| UM | 104 | 90 | 13 | 107 | 83 | 16 | 0.26 | −0.078 |
| rs57095329 | AA | AG | GG | AA | AG | GG | ||
| CM | 57 | 50 | 3 | 62 | 41 | 7 |
| −0.212 |
| UM | 118 | 74 | 15 | 116 | 78 | 13 | 0.47 | 0.047 |
| rs2910164 | CC | CG | GG | CC | CG | GG | ||
| CM | 26 | 65 | 19 | 31 | 55 | 24 | 0.0503 | −0.186 |
| UM | 66 | 100 | 41 | 65 | 102 | 40 | 0.78 | 0.019 |
Bold indicates the statistically significant difference.
Genotype and allele frequencies of miRSNPs and their relation to risk of CM
| Genotypes | CM | UM |
| OR (95% CI) |
|---|---|---|---|---|
| rs895819 (microRNA‐27a) | 0.23 | |||
| TT | 47 (42.7) | 104 (50.2) | ||
| TC | 51 (46.4) | 90 (43.5) | 0.36 (TC vs. TT) | 1.25 (0.77–2.04) |
| CC | 12 (10.9) | 13 (6.3) | 0.10 (CC vs. TT) | 2.04 (0.87–4.81) |
| Dominant model | 63 (57.3) | 103 (49.8) | 0.20 (TT vs. TC+CC) | 1.35 (0.85–2.16) |
| Over‐dominant model | 59 (53.6) | 117 (56.5) | 0.62 (TT+CC vs. TC) | 1.12 (0.71–1.79) |
| Recessive model | 98 (89.1) | 194 (93.7) | 0.15 (TC+TT vs. CC) | 1.83 (0.80–4.15) |
| Additive model | 0.1 | 0.74 (0.51–1.06) | ||
| Multiplicative model | 0.1 | 1.35 (0.94–1.95) | ||
| T allele | 145 (0.66) | 298 (0.72) | ||
| C allele | 75 (0.34) | 116 (0.28) | 0.11 (C vs. T allele) | 1.33 (0.93–1.89) |
| rs57095329 (microRNA‐146a) | 0.097 | |||
| AA | 57 (51.8) | 118 (57.0) | ||
| AG | 50 (45.5) | 74 (35.75) | 0.17 (AG vs. AA) | 1.40 (0.87–2.26) |
| GG | 3 (2.7) | 15 (7.25) | 0.16 (GG vs. AA) | 0.41 (0.11–1.49) |
| Dominant model | 53 (48.2) | 89 (43) | 0.38 (AA vs. AG+GG) | 1.23 (0.77–1.96) |
| Over‐dominant model | 60 (54.5) | 133 (64.25) | 0.09 (AA+GG vs. AG) | 1.50 (0.94–2.40) |
| Recessive model | 107 (97.3) | 192 (92.75) | 0.10 (AG+AA vs. GG) | 0.36 (0.10–1.26) |
| Additive model | 0.93 | 0.98 (0.67–1.44) | ||
| Multiplicative model | 0.93 | 1.02 (0.69–1.49) | ||
| A allele | 164 (0.745) | 310 (0.749) | ||
| G allele | 56 (0.255) | 104 (0.251) | 0.92 (G vs. A allele) | 1.01(0.70–1.48) |
| rs2910164 (microRNA‐146a) | 0.171 | |||
| CC | 26 (23.6) | 66 (31.9) | ||
| CG | 65 (59.1) | 100 (48.3) | 0.07(CG vs. CC) | 1.65 (0.95–2.86) |
| GG | 19 (17.3) | 41 (19.8) | 0.65 (GG vs. CC) | 1.18 (0.58–2.39) |
| Dominant model | 84 (76.4) | 141 (68.1) | 0.12 (CC vs. CG+GG) | 1.51 (0.89–2.56) |
| Over‐dominant model | 45 (40.9) | 107 (51.7) | 0.07 (CC+GG vs. CG) | 1.55 (0.97–2.47) |
| Recessive model | 91 (82.7) | 166 (80.2) | 0.58 (CG+CC vs. GG) | 0.85 (0.46–1.54) |
| Additive model | 0.48 | 0.89 (0.63–1.24) | ||
| Multiplicative model | 0.48 | 1.13 (0.81–1.58) | ||
| C allele | 118 (0.532) | 232 (0.560) | ||
| G allele | 102 (0.468) | 182 (0.440) | 0.56 (G vs. C allele) | 1.10 (0.79–1.53) |
Figure 4LD analysis of two microRNA SNPs displayed in D’ and r 2 by Haploview software version 4.2
Haplotype analysis of rs57095329 and rs2910164 for the risk of CM
| Haplotype | Sequence | Frequency in CM | Frequency in UM |
|
| OR (95%CI) |
|---|---|---|---|---|---|---|
| H1 | AC | 0.5045 | 0.5362 | 0.045 | 0.181 | 0.84 (0.41–1.73) |
| H2 | GG | 0.2272 | 0.2270 | 0.542 | 1.001 (0.94–1.07) | |
| H3 | AG | 0.2409 | 0.2126 | 0.776 | 1.39 (0.51–3.81) | |
| H4 | GC | 0.0273 | 0.0242 | 1 | 0 |
Haplotype analysis by SNPAnalyzer 2.0 version 4.2 (Yoo et al., 2008).